# Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

> **NCT00618501** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 50 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** imatinib mesylate
- **DRUG:** leucovorin calcium
- **DRUG:** methotrexate
- **DRUG:** prednisolone
- **DRUG:** therapeutic hydrocortisone
- **DRUG:** vincristine sulfate
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00618501
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00618501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00618501, "Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00618501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*